Cover Image
市場調查報告書

EpiCast Report:全球免疫缺乏病毒(HIV)免疫學的預測

EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 260973
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全球免疫缺乏病毒(HIV)免疫學的預測 EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023
出版日期: 2015年09月07日 內容資訊: 英文 65 Pages
簡介

全球主要8國免疫缺乏病毒(HIV)疾病數量、從2013年的339萬4,507件預計2023年將擴大至412萬6,502件。HIV的流行透過使用保險套與停止共用注射針頭等預防疾病的公共政策宣導結果、大部分國家在2007年後已趨緩。雖然感染者整體人數減少、因透過人工生殖技術(ART)幫助HIV病毒感染者、HIV患者人數全球持續增加。HIV感染的過輕診斷也讓人產生對全球公眾衛生的擔憂。

本報告針對全球主要10國(HIV(免疫缺乏病毒)發症狀況與今後預測分析、HIV特徵、各國詳細狀況、今後10年發症數預測值調查、推算。

第1章 目錄

第2章 介紹

第3章 免疫學

  • 疾病背景
  • 風險因素與併發症
    • 風險因素
      • 無防備的性交
      • 污染血液的曝露
      • 靜脈注射藥物的使用
      • 其他性病感染
      • 母子感染
      • 年齡
    • 併發症
      • C型肝炎
      • 結核(TB)
  • 世界各國動向
    • 美國
    • EU5國
    • 巴西、中國、日本
  • 預測方法
    • 情報來源
    • 未使用情報來源
    • 預測前提條件與方法
  • 免疫學預測(8大市場)
    • 有病數量
    • 年齡分類有病數量
    • 性別有病數量
    • 年齡調整有病率
    • 人工生殖技術(ART)病例
    • 孕婦HIV病例
  • 日本免疫學預測
    • HIV診斷後患病期間20年病例
    • 有病期間20年年齡分類病例數
    • 有病期間20年性別病例數
    • 有病期間20年年齡調整後有病率
    • 人工生殖技術(ART)病例
    • 孕婦HIV病例
  • 考察
    • 關於免疫學預測
    • 本次分析限制
    • 分析優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER007-15

The human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, and the infected person becomes more susceptible to other infections. It can take as long as two to 10 years for a person infected with HIV to develop acquired immunodeficiency syndrome (AIDS), which is the most advanced stage of HIV; however, treatment with antiretroviral drugs can slow the process even further.

In 2013, there were 3,394,507 total prevalent cases of HIV in the 8MM, with 1,218,323 cases in the US and 641,500 in the 5EU markets combined. Japan had 18,428 20-year diagnosed prevalent cases of HIV in 2013. GlobalData epidemiologists forecast that the total prevalent cases of HIV in the 8MM will increase to 4,126,502 in the 8MM by 2023. Additionally, GlobalData epidemiologists forecast that the 20-year diagnosed prevalent cases of HIV in Japan will increase to 27,264 cases by 2023.

GlobalData epidemiologists reviewed national and international HIV and AIDS databases and used reliable data to build this forecast. The total prevalent cases of HIV were segmented by age and sex using country-specific data, whenever available; when data were not available, appropriate proxies were used. For Japan, GlobalData epidemiologists provide an alternative forecast for the 20-year diagnosed prevalent cases of HIV, which better aligns with the ART market sales data after consolidation. GlobalData epidemiologists also provide an alternative forecast for Japan, based on the reported HIV prevalent cases.

Scope

  • The HIV EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for HIV in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the total prevalent cases of HIV segmented by sex and age (beginning at 0 years and ending at =85 years) in the 8MM, excluding Japan, for which 20-year diagnosed prevalent cases, is forecast. In addition, the report provides the prevalent cases of HIV-positive pregnant women in the total prevalent HIV cases, as well as the total prevalent cases treated by antiretroviral drugs.
  • The HIV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global HIV market.
  • Quantify patient populations in the global HIV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for HIV therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Brazil, China, and Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for HIV in the 8MM (2013-2023)
    • 3.5.1. Total Prevalent Cases of HIV
    • 3.5.2. Age-Specific Total Prevalent Cases of HIV
    • 3.5.3. Sex-Specific Total Prevalent Cases of HIV
    • 3.5.4. Age-Standardized Total Prevalence of HIV
    • 3.5.5. HIV Cases Treated with ART
    • 3.5.6. Cases of HIV in Pregnant Women
  • 3.6. Epidemiological Forecast for HIV in Japan (2013-2023)
    • 3.6.1. 20-Year Diagnosed Prevalent Cases of HIV
    • 3.6.2. Age-Specific 20-Year Diagnosed Prevalent Cases of HIV
    • 3.6.3. Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV
    • 3.6.4. Age-Standardized 20-Year Diagnosed Prevalence of HIV
    • 3.6.5. HIV Cases Treated with ART
    • 3.6.6. Cases of HIV in Pregnant Women
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Physicians and Specialists Included in this Study
  • 4.3. Primary Research - Prescriber Survey
  • 4.4. About the Authors
    • 4.4.1. Epidemiologists
    • 4.4.2. Reviewers
    • 4.4.3. Global Director of Therapy Analysis and Epidemiology
    • 4.4.4. Global Head of Healthcare
  • 4.5. About GlobalData
  • 4.6. About EpiCast
  • 4.7. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for HIV
  • Table 2: US, Total Prevalence of HIV in Men and Women (%), Ages ≥13 Years, 2006-2010
  • Table 3: 5EU, Total Prevalence of HIV in Men (%), All Ages, Selected Years, 2001-2013
  • Table 4: 5EU, Total Prevalence of HIV in Women (%), All Ages, Selected Years, 2001-2013
  • Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of HIV
  • Table 6: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan
  • Table 7: 9MM, Sources Used to Forecast the ART Treatment Rate Among the Total Prevalent Cases of HIV
  • Table 8: 9MM, Sources Used to Forecast the Prevalent Cases of HIV-Positive Pregnant Women
  • Table 9: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
  • Table 10: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N (Row %), 2013
  • Table 11: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N (Row %), 2013
  • Table 12: 8MM, HIV Cases Treated with ART, N (Col %), All Ages, Both Sexes, Selected Years 2013-2023
  • Table 13: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
  • Table 14: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N (Row %), 2013
  • Table 15: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013
  • Table 16: Japan, HIV Cases Treated with ART, All Ages, Both Sexes, N, Selected Years 2013-2023
  • Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N, 2013
  • Figure 3: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N, 2013
  • Figure 4: 8MM, Age-Standardized Total Prevalence of HIV, All Ages, N, 2013
  • Figure 5: 8MM, Cases of HIV in Pregnant Women Among the Total Prevalent Cases of HIV in Women, N, 2013 and 2023
  • Figure 6: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
  • Figure 7: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N, 2013
  • Figure 8: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013
  • Figure 9: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV, All Ages, N, 2013
  • Figure 10:Japan, Cases of HIV in Pregnant Women Among Diagnosed Prevalent Cases of HIV in Women, N, 2013 and 2023
Back to Top